Prostatic Diseases: Clinical Trials

59 trials for Prostatic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

59 unknown. 59 Phase 3, 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 359Unknown 59
Phase 212Unknown 12

Follow Prostatic Diseases: new trials by email Literature Review of Prostatic Diseases trials Research Report on Prostatic Diseases

Trials (filtered) newest first · largest first

All 59 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage
Enzalutamide 40 MG, Docetaxel injection - Prostate Cancer, Castrate Resistant Prostate Cancer
Phase 2 / Phase 3UnknownZhongnan Hospital1202024-06-012024-02-28
Outcomes of MIST for BPH: A Single-Institution Prospective Study
Rezum, iTind - Benign Prostatic Hyperplasia
Phase 3UnknownUniversity of Manitoba202024-03-012024-02-23
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
68Ga-PSMA-11, PET/CT or PET/MRI - Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer
Phase 3UnknownTelix Pharmaceuticals (Innovations) Pty Limited1102023-07-192024-07-03
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
rhPSMA-7.3 (18F) - Prostate Cancer
Phase 3UnknownMidLantic Urology1132023-04-272024-05-24
Tranexamic Acid's Effects in Patients Undergoing Laparoscopic Radical Prostatectomy
Tranexamic acid, Placebo - Prostate Cancer
Phase 3UnknownInstituto do Cancer do Estado de São Paulo1222023-04-012023-04-18
Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7
Radiopharmaceutical 18F-JK-PSMA-7, Radiopharmaceutical 18F-Fluorocholine - Prostate Cancer, 18F- Fluorocholine
Phase 3UnknownITEL Telecomunicazioni Srl1062022-12-192024-05-22
Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH
Prostatic Artery Embolization (PAE), Pharmacotherapy - Benign Prostatic Hyperplasia, Pharmacotherapy
Phase 3UnknownDominik Abt4252021-09-012021-01-26
PROARTE -PROstate ARTery to Reduce the Symptoms of Benign Prostatic Hyperplasia
Prostate Artery Embolization, Sham Prostate Artery Embolization - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Phase 3UnknownSociety of Interventional Radiology Foundation1082021-08-012021-03-19
Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients
Al18F-PSMA-617, 68Ga-PSMA-617 - Prostate Cancer
Phase 2 / Phase 3UnknownPeking Union Medical College Hospital1002021-07-012023-05-03
Efficacy of α-blocker or 5-ARI Withdrawal to Continued Combination Therapy on the Maintenance of LUTS in Men With BPH
alpha-blocker or 5-ARI withdrawal, Maintenance of alpha-blocker and 5-ARI - Prostatic Hyperplasia, Prostate Hyperplasia
Phase 3UnknownGangnam Severance Hospital3002020-12-082021-08-27
68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients
68Ga-PSMA-617, 68Ga-P16-093 - Prostate Cancer
Phase 2 / Phase 3UnknownPeking Union Medical College Hospital502020-10-012022-08-09
Impact of Atorvastatin on Prostate Cancer Progression During ADT
Atorvastatin 80mg, Placebo oral capsule - Metastatic Prostate Cancer, Recurrent Prostate Cancer
Phase 3UnknownTampere University Hospital4002019-08-152022-10-21
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
Ipilimumab 5 MG/ML, Nivolumab 10 MG/ML, Docetaxel - Metastatic Hormone-sensitive Prostate Cancer
Phase 2 / Phase 3UnknownSpanish Oncology Genito-Urinary Group1352019-02-112022-10-26
Comparison of PET With 68GA-PSMA-11 and 18F-Fluorocholine for Recurrence in Men With Prostate Cancer
68Ga-PSMA-11 PET, 18F-FCH PET - Prostate Cancer
Phase 3UnknownCentral Hospital, Nancy, France462019-02-012018-08-09
Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency
Everolimus, Placebo - Prostate Cancer
Phase 3UnknownTianjin Medical University Second Hospital1202019-01-012018-07-09
18F-DCFPyL PET-CT Scan and Prostate Cancer
18F-DCFPyL - Prostate Cancer Adenocarcinoma
Phase 2 / Phase 3UnknownLida Jafari1702018-07-222019-02-25
A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
SHR3680, Bicalutamide - Prostate Cancer, Hormone-Dependent Prostate Cancer
Phase 3UnknownJiangsu HengRui Medicine Co., Ltd.6542018-05-302021-03-02
Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy
Radium-223 chloride, Rhenium-188-HEDP - Prostate Cancer Metastatic to Bone
Phase 3UnknownAmsterdam UMC, location VUmc4022018-05-162020-11-17
Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients
68Ga-PSMA-11, 18F-Choline PET-CT - Prostate Cancer
Phase 2 / Phase 3UnknownCentral Hospital, Nancy, France332018-01-022017-11-17
Effects of Proxelan Somministration in Patients With Chronic Prostatitis
Proxelan - Chronic Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Phase 3UnknownUniversity of Pisa302017-02-162018-08-14

Showing 20 of 59. Sign in to see all of them.

Narrower conditions

Prostatic Neoplasms (52)  ·  Prostatic Hyperplasia (6)  ·  Neoplasms (4)  ·  Breast Neoplasms (2)  ·  Erectile Dysfunction (2)  ·  Osteoporosis (2)  ·  Pain (2)  ·  Rectal Neoplasms (2)  ·  Urinary Incontinence (2)  ·  Anemia (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Carcinoma, Renal Cell (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)

Broader conditions

Genital Diseases (59)  ·  Genital Diseases, Male (59)  ·  Male Urogenital Diseases (59)  ·  Urogenital Diseases (59)  ·  Genital Neoplasms, Male (52)  ·  Neoplasms by Site (52)  ·  Urogenital Neoplasms (52)  ·  Neoplasms (48)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Signs and Symptoms (7)  ·  Female Urogenital Diseases (4)  ·  Female Urogenital Diseases and Pregnancy Complications (4)  ·  Mental Disorders (4)  ·  Urologic Diseases (4)

Interventions

Docetaxel (7)  ·  Androgen Antagonists (4)  ·  bicalutamide (3)  ·  Flutamide (2)  ·  Gonadotropin-Releasing Hormone (2)  ·  Goserelin (2)  ·  Leuprolide (2)  ·  Radiotherapy (2)  ·  Tamsulosin (2)  ·  Triptorelin Pamoate (2)  ·  enzalutamide (2)  ·  18F-JK-PSMA-7 (1)  ·  2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1)  ·  Absorptiometry, Photon (1)  ·  Adrenergic alpha-Antagonists (1)

Sponsors

Central Hospital, Nancy, France (2)  ·  IlDong Pharmaceutical Co Ltd (2)  ·  Peking Union Medical College Hospital (2)  ·  Royal Marsden NHS Foundation Trust (2)  ·  Scandinavian Prostate Cancer Group (2)  ·  VA Puget Sound Health Care System (2)  ·  A.O.U. San Giovanni Battista di Torino, Italy (1)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Amphia Hospital (1)  ·  Amsterdam UMC, location VUmc (1)  ·  Anders Widmark (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Beijing Hospital (1)  ·  Brooke Army Medical Center (1)  ·  Canadian Urology Research Consortium (1)

Countries

United States (11)  ·  Canada (10)  ·  China (9)  ·  Denmark (5)  ·  United Kingdom (5)  ·  France (4)  ·  Sweden (4)  ·  Finland (3)  ·  Italy (3)  ·  Netherlands (3)  ·  Norway (3)  ·  South Korea (3)  ·  Australia (2)  ·  Poland (2)  ·  Bulgaria (1)

Top investigators

Kent E Wallner, MD (2)  ·  Alan Pollack, MD, PhD (1)  ·  Anders Widmark, Prof MD (1)  ·  Andreas Josefsson, PhD (1)  ·  Anthony Joshua, MD (1)  ·  Bo Abrahamsen, MD, PhD, Professor (1)  ·  Carey Robertson, MD (1)  ·  Claus Dahl, MD (1)  ·  Daniel Eberli, PD Dr. PhD (1)  ·  Deborah A. Kuban, MD (1)  ·  Dingwei Ye, M.D. (1)  ·  Dominik Abt, MD (1)  ·  Franck Bladou, MD (1)

Results publications

PMID 11895205, PMID 14499682, PMID 14630265, PMID 15840561, PMID 18542722, PMID 20797824, PMID 20800404, PMID 21350618, PMID 21844889, PMID 23465742, PMID 23559588, PMID 23797218, PMID 24072344, PMID 24207135, PMID 24285576, PMID 24920079, PMID 25203127, PMID 25411132, PMID 25447835, PMID 26707868, PMID 27155740, PMID 27363387, PMID 28433432, PMID 28518227, PMID 28581398, PMID 28760403, PMID 29388336, PMID 30017404, PMID 30027419, PMID 30174470, PMID 30245169, PMID 30389823, PMID 30448957, PMID 30507748, PMID 31324713, PMID 31516367, PMID 31708295, PMID 31836681, PMID 31836682, PMID 34557930, PMID 34895925, PMID 35487730, PMID 35569466, PMID 36075260, PMID 36727866, PMID 36884035, PMID 36996380, PMID 37973477, PMID 39419035, PMID 39663356

NIH funding

2005 (1), 2016 (1), 2017 (1), U10CA031946 (1)